TAVR Durability Becomes Irrelevant after TRANSIT Outcomes

The international registry TRANSIT has shown treating degenerated transcatheter aortic valves (TAVs) with a second TAVR is safe and effective. These finding are of crucial importance to the definite adoption of TAVR in the lower risk, younger population. 

durabilidad del TAVI pasa a un segundo plano con los resultados del TRANSIT

Transcatheter aortic valve replacement (TAVR) has determined a paradigm shift in severe aortic stenosis treatment.  Technological innovation and growing expertise have allowed to significantly reduce adverse events compared to the early days of TAVR. 

However, durability was, or still is, a question to be answered over time. After this registry outcomes, TAV durability becomes irrelevant, since they provide the solution to this problem. 

Researchers from 28 centers around the world included 172 TAVR patients receiving a second TAVR for degenerated first TAV (33%), regurgitant TAV (56%) or a combination of both (11%). Most patients (73.5%) were in functional class III-IV.

According to VARC 2 criteria (Valve Academic Research Consortium 2) procedural success rate was 79% as a consequence of 14% residual gradient and 7% regurgitation. 


Read also: Myocarditis and mRNA COVID-19 Vaccines: New Information from the CDC.


All-cause mortality one year after the second procedure resulted 10% while new hospitalization and functional class III-IV rates resulted 7.6% and 5.8% respectively. There were no significant differences between subgroups.

There were no valve thrombosis cases.

Conclusion

Transcatheter implantation of a second prosthesis in select patients with degenerated or regurgitant TAVs is feasible, and has high success and low complications rates. 

Original Title: Transcatheter Aortic Valve Replacement for Degenerated Transcatheter Aortic Valves: The TRANSIT International Project.

Reference: Luca Testa et al. Circ Cardiovasc Interv. 2021 Jun;14(6):e010440. doi: 10.1161/CIRCINTERVENTIONS.120.010440.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

TCT 2024 – EVOLVED trial: Early Intervention for Patients with Severe Asymptomatic Aortic Stenosis and Myocardial Fibrosis?

Treating symptomatic severe aortic stenosis (AS) with aortic valve replacement is currently considered a class I recommendation, evidence level B, according to the current...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...